Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New evaluation therapies for sepsis.

G Deby-Dupont1, P P Damas, M Lamy

  • 1Department of Anaesthesiology and Intensive Care, University Hospital, B 35, and Centre for Oxygen Research and Development (CORD), Institut de Chimie, B6a, Domaine Universitaire du Sart Tilman, 4000 Liège, Belgium.

Current Opinion in Anaesthesiology
|October 3, 2006
PubMed
Summary

Recent sepsis and septic shock treatments show disappointing results from antimediator therapies. Ongoing research explores new approaches and analyzes past clinical trial failures to improve patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Culture and Immunomodulation of Equine Muscle-Derived Mesenchymal Stromal Cells: A Comparative Study of Innovative 2D versus 3D Models Using Equine Platelet Lysate.

Cells·2024
Same author

Propofol protects cell proteins against the oxidation induced by a simultaneous generation of superoxide anion and nitric oxide.

Veterinary anaesthesia and analgesia·2017
Same author

Acepromazine modulates cell differentiation: in vitro experiments on monocytes stimulated by Chlamydia pneumoniae toxins.

Veterinary anaesthesia and analgesia·2017
Same author

An immunological method to combine the measurement of active and total myeloperoxidase on the same biological fluid, and its application in finding inhibitors which interact directly with the enzyme.

Free radical research·2015
Same author

Modulatory effects of non-steroidal anti-inflammatory drugs on the luminol and lucigenin amplified chemiluminescence of equine neutrophils.

Veterinary research communications·2011
Same author

In vivo administration of acepromazine or promethazine to horse decreases the reactive oxygen species production response of subsequently isolated neutrophils to stimulation with phorbol myristate acetate.

Journal of veterinary pharmacology and therapeutics·2010

Area of Science:

  • Critical care medicine
  • Infectious diseases
  • Pharmacology

Background:

  • Sepsis and septic shock remain leading causes of mortality worldwide.
  • Effective treatment strategies are urgently needed to improve patient survival rates.
  • Recent advances in understanding sepsis pathophysiology have spurred novel therapeutic development.

Purpose of the Study:

  • To review and analyze recent literature (last 2 years) on sepsis and septic shock treatment.
  • To evaluate the efficacy of various therapeutic approaches, particularly antimediator therapies.
  • To identify reasons for the limited success of past clinical trials in sepsis treatment.

Main Methods:

  • Comprehensive literature search of databases for studies published in the last two years.

Related Experiment Videos

  • Systematic review and critical analysis of clinical trial data, focusing on phase II and III studies.
  • Synthesis of findings regarding the effectiveness of different treatment modalities.

    • Main Results:

    • Most antimediator therapies evaluated in recent phase II/III clinical trials have shown disappointing outcomes.
    • Despite setbacks, numerous novel therapeutic strategies are under investigation or in development.
    • Published analyses highlight critical factors contributing to the failure of previous clinical trials.

    Conclusions:

    • Current antimediator therapies for sepsis and septic shock have largely failed to demonstrate significant clinical benefit.
    • Future research must focus on innovative therapeutic targets and rigorous trial design.
    • Understanding the reasons behind past failures is crucial for advancing sepsis treatment.